8-K/A filed September 30, 2021, 7:59 PM ET ticker TPST CIK 0001544227

leadership confidence high sentiment neutral materiality 0.20

Tempest Therapeutics corrects option grant details for new CFO Maestas

Tempest Therapeutics, Inc.

Nicholas Maestas appointed VP, Strategy & Finance and principal financial officer effective July 12, 2021.
Annual base salary of $325,000 with target performance bonus of 30% of base salary.
Option to purchase 23,225 shares at July 12 closing price; vesting: 25% after one year then monthly over 36 months.
This amendment corrects a clerical error in the original 8-K regarding the option grant terms.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Nicholas Maestas

vice president, strategy and finance and principal financial officer

TPST · Tempest Therapeutics, Inc.

Effective: 2021-07-12
Filed: September 30, 2021, 7:59 PM ET

On July 12, 2021, Nicholas Maestas, age 41, joined the Company as vice president, strategy and finance and is the Company’s principal financial officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Nicholas Maestas was appointed as vice president, strategy and finance and principal financial officer at Tempest Therapeutics, Inc..

Action: appointed
Role: vice president, strategy and finance and principal financial officer

Exact text from the filing

On July 12, 2021, Nicholas Maestas, age 41, joined the Company as vice president, strategy and finance and is the Company’s principal financial officer.

View on SEC.gov

Tempest Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-287569

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.